Literature DB >> 8412642

Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients.

A Alonso-Ruiz1, M Calabozo, F Perez-Ruiz, L Mancebo.   

Abstract

Toxic oil syndrome is a multisystemic, epidemic disease that appeared in Spain in 1981, related to the intake of rapeseed cooking oil sold in bulk. It affected 19,748 people, of whom 457 died. The toxic substance was never identified. We report the 8-year follow-up of a cohort of 332 patients. The disease was usually severe and disabling during the first 2 years, but the clinical condition of most of the patients improved thereafter. The acute phase lasted 2 months, and was characterized by pulmonary edema, rash, eosinophilia, and myalgia. During the intermediate phase (second to fourth months), severe myalgia, skin tenderness, subcutaneous edema, altered liver function, and pulmonary hypertension developed. Later on, an early chronic phase developed, from the fourth month to the end of the second year. It was marked by scleroderma, sicca syndrome, polyneuropathy, joint contractures, weight loss, and functional limitations. The clinical manifestations improved during the late chronic phase. Its most prominent clinical features were muscle cramps, chronic musculoskeletal pain, chronic lung disease, Raynaud phenomenon, carpal tunnel syndrome, and psychologic disturbances. Only 9% of the patients achieved remission after the acute phase, the rest developing late clinical manifestations of the disease. The severity of the chronic manifestations was rather variable. At the end of the 8-year follow-up, there were 10 TOS-related deaths (3%), 47% of the patients had some kind of complaint, albeit subtle in most cases, and 16% showed organic involvement related to TOS. The most important pathologic features of TOS were widespread interstitial infiltrates, non-necrotizing angiitis, endothelial proliferation, and tissue fibrosis. Toxic oil syndrome is a dramatic example of an induced scleroderma-like syndrome, similar to the eosinophilia-myalgia syndrome. Patients with EMS may develop some of the late clinical features of TOS in the years to come.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8412642     DOI: 10.1097/00005792-199309000-00001

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  7 in total

Review 1.  Drug-induced cholestasis.

Authors:  Manmeet S Padda; Mayra Sanchez; Abbasi J Akhtar; James L Boyer
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

Review 2.  Environmental risk factors of systemic sclerosis.

Authors:  Isabelle Marie; Jean-François Gehanno
Journal:  Semin Immunopathol       Date:  2015-07-04       Impact factor: 9.623

3.  Chronic myeloid leukaemia and allogenic bone marrow transplantation in a patient with toxic oil syndrome.

Authors:  P Llamas-Sillero; M Gómez-Roncero; R Forés; R Cabrera; J L Díez; M N Fernández
Journal:  Postgrad Med J       Date:  1995-07       Impact factor: 2.401

4.  Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases.

Authors:  S A Bell; H Faust; A Schmid; M Meurer
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

Review 5.  The toxic oil syndrome: an example of an exogenously induced autoimmune reaction. Toxic oil syndrome.

Authors:  S A Bell
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

6.  Pharmacogenetic profile of xenobiotic enzyme metabolism in survivors of the Spanish toxic oil syndrome.

Authors:  M G Ladona; M Izquierdo-Martinez; M P Posada de la Paz; R de la Torre; C Ampurdanés; J Segura; E J Sanz
Journal:  Environ Health Perspect       Date:  2001-04       Impact factor: 9.031

7.  Severe eosinophilic syndrome associated with the use of probiotic supplements: a new entity?

Authors:  Fabian A Mendoza; Shivani Purohit; Lawrence Kenyon; Sergio A Jimenez
Journal:  Case Rep Rheumatol       Date:  2012-12-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.